Evaluation of commercially available aroA delated gene E. coli O78 vaccine in commercial broiler chickens under Middle East simulating field conditions

Abstract The broiler industry in the Middle East (ME) faces many challenges related to bacterial infections, including M. gallisepticum, M. synoviae, E. coli, and other gram-negative bacteria, exacerbated by various errors in the brooding process. Antibiotics use in the first three days of life, suc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hussein M. Galal, M. I. Abdrabou, Ahmed H. I. Faraag, C. K. Mah, Azza M. Tawfek
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7089b17490bc4964b408befca0a5299e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7089b17490bc4964b408befca0a5299e
record_format	dspace
spelling	oai:doaj.org-article:7089b17490bc4964b408befca0a5299e2021-12-02T10:49:16ZEvaluation of commercially available aroA delated gene E. coli O78 vaccine in commercial broiler chickens under Middle East simulating field conditions10.1038/s41598-021-81523-x2045-2322https://doaj.org/article/7089b17490bc4964b408befca0a5299e2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81523-xhttps://doaj.org/toc/2045-2322Abstract The broiler industry in the Middle East (ME) faces many challenges related to bacterial infections, including M. gallisepticum, M. synoviae, E. coli, and other gram-negative bacteria, exacerbated by various errors in the brooding process. Antibiotics use in the first three days of life, such as Linco-Spectin 100 SP, tilmicosin, enrofloxacin, tylosin, colistin, and doxycycline, is the trend in the market to control such challenges. This study aimed to evaluate the efficacy of the newly introduced aroA E. coli vaccine (Poulvac E. coli) and its ability to reduce over-reliance on the heavy use of antibiotics in the ME. The study was conducted on 160 broiler chicks, divided into eight even groups. Each group was treated differently in terms of antibiotic therapy and ages at the time of Poulvac E. coli administration and the challenge of virulent avian pathogenic E. coli (APEC), serotype O78. Spray application of Poulvac E. coli at seven days of age plus Linco-Spectin 100 SP during the first three days provided the best results for zero mortality after challenge with APEC, while Poulvac E. coli at seven days with enrofloxacin during the early three days resulted in 10% mortality. Poulvac E. coli hatchery vaccination protected birds against mortality but reduced body weight gain compared to the 7-day group vaccinated with Linco-Spectin 100 SP during the first three days. Poulvac E. coli given on day one or day seven did not affect the immune response to concurrent respiratory viral vaccines and, in some cases, improved response. This study shows that Poulvac E. coli at seven days of age, together with Linco-Spectin 100 during the first three days, has produced the best results in terms of protection and performance in the ME high presence of avian pathogenic E. coli field challenge.Hussein M. GalalM. I. AbdrabouAhmed H. I. FaraagC. K. MahAzza M. TawfekNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hussein M. Galal M. I. Abdrabou Ahmed H. I. Faraag C. K. Mah Azza M. Tawfek Evaluation of commercially available aroA delated gene E. coli O78 vaccine in commercial broiler chickens under Middle East simulating field conditions
description	Abstract The broiler industry in the Middle East (ME) faces many challenges related to bacterial infections, including M. gallisepticum, M. synoviae, E. coli, and other gram-negative bacteria, exacerbated by various errors in the brooding process. Antibiotics use in the first three days of life, such as Linco-Spectin 100 SP, tilmicosin, enrofloxacin, tylosin, colistin, and doxycycline, is the trend in the market to control such challenges. This study aimed to evaluate the efficacy of the newly introduced aroA E. coli vaccine (Poulvac E. coli) and its ability to reduce over-reliance on the heavy use of antibiotics in the ME. The study was conducted on 160 broiler chicks, divided into eight even groups. Each group was treated differently in terms of antibiotic therapy and ages at the time of Poulvac E. coli administration and the challenge of virulent avian pathogenic E. coli (APEC), serotype O78. Spray application of Poulvac E. coli at seven days of age plus Linco-Spectin 100 SP during the first three days provided the best results for zero mortality after challenge with APEC, while Poulvac E. coli at seven days with enrofloxacin during the early three days resulted in 10% mortality. Poulvac E. coli hatchery vaccination protected birds against mortality but reduced body weight gain compared to the 7-day group vaccinated with Linco-Spectin 100 SP during the first three days. Poulvac E. coli given on day one or day seven did not affect the immune response to concurrent respiratory viral vaccines and, in some cases, improved response. This study shows that Poulvac E. coli at seven days of age, together with Linco-Spectin 100 during the first three days, has produced the best results in terms of protection and performance in the ME high presence of avian pathogenic E. coli field challenge.
format	article
author	Hussein M. Galal M. I. Abdrabou Ahmed H. I. Faraag C. K. Mah Azza M. Tawfek
author_facet	Hussein M. Galal M. I. Abdrabou Ahmed H. I. Faraag C. K. Mah Azza M. Tawfek
author_sort	Hussein M. Galal
title	Evaluation of commercially available aroA delated gene E. coli O78 vaccine in commercial broiler chickens under Middle East simulating field conditions
title_short	Evaluation of commercially available aroA delated gene E. coli O78 vaccine in commercial broiler chickens under Middle East simulating field conditions
title_full	Evaluation of commercially available aroA delated gene E. coli O78 vaccine in commercial broiler chickens under Middle East simulating field conditions
title_fullStr	Evaluation of commercially available aroA delated gene E. coli O78 vaccine in commercial broiler chickens under Middle East simulating field conditions
title_full_unstemmed	Evaluation of commercially available aroA delated gene E. coli O78 vaccine in commercial broiler chickens under Middle East simulating field conditions
title_sort	evaluation of commercially available aroa delated gene e. coli o78 vaccine in commercial broiler chickens under middle east simulating field conditions
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7089b17490bc4964b408befca0a5299e
work_keys_str_mv	AT husseinmgalal evaluationofcommerciallyavailablearoadelatedgeneecolio78vaccineincommercialbroilerchickensundermiddleeastsimulatingfieldconditions AT miabdrabou evaluationofcommerciallyavailablearoadelatedgeneecolio78vaccineincommercialbroilerchickensundermiddleeastsimulatingfieldconditions AT ahmedhifaraag evaluationofcommerciallyavailablearoadelatedgeneecolio78vaccineincommercialbroilerchickensundermiddleeastsimulatingfieldconditions AT ckmah evaluationofcommerciallyavailablearoadelatedgeneecolio78vaccineincommercialbroilerchickensundermiddleeastsimulatingfieldconditions AT azzamtawfek evaluationofcommerciallyavailablearoadelatedgeneecolio78vaccineincommercialbroilerchickensundermiddleeastsimulatingfieldconditions
_version_	1718396597109260288

Evaluation of commercially available aroA delated gene E. coli O78 vaccine in commercial broiler chickens under Middle East simulating field conditions

Ejemplares similares